Using tetracyclines to treat osteoporotic/osteopenic bone loss: From the basic science laboratory to the clinic

Jeffrey B. Payne, Lorne M. Golub

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Periodontitis (progressive inflammatory disease characterized by alveolar bone loss, a major cause of tooth loss worldwide) is associated with both systemic osteoporosis and its milder form, osteopenia. Tetracyclines, by virtue of their non-antimicrobial pro-anabolic and anti-catabolic properties, are excellent candidate pharmaceuticals to simultaneously treat these local and systemic disorders. This paper reviews the foundational basic science and translational research which lead to a pivotal multicenter randomized clinical trial in postmenopausal women with both periodontitis and systemic (skeletal) osteopenia. This trial was designed primarily to examine whether subantimicrobial dose doxycycline (SDD) could reduce progressive alveolar (oral) bone loss associated with periodontitis and, secondarily, whether SDD could reduce systemic bone loss in the same subjects. This paper describes the efficacy and safety findings from this clinical trial and also outlines future directions using this promising and novel approach to manage both oral and systemic bone loss.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalPharmacological Research
Volume63
Issue number2
DOIs
StatePublished - Feb 2011

Keywords

  • Collagenases
  • Osteopenia
  • Osteoporosis
  • Periodontitis
  • Postmenopausal women
  • Subantimicrobial dose doxycycline

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Using tetracyclines to treat osteoporotic/osteopenic bone loss: From the basic science laboratory to the clinic'. Together they form a unique fingerprint.

  • Cite this